Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2024-08-14 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
关于子公司注射用头孢唑肟钠通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Lingkang Pharmaceutical Group Co., Ltd. regarding its subsidiary's drug "Injection Cefazolin Sodium" passing the generic drug consistency evaluation. It includes regulatory approval details from the National Medical Products Administration, drug registration information, and the impact on the company. The document is relatively short (1607 characters) and serves as an official announcement of a regulatory approval event rather than a detailed financial or management report. It does not contain financial statements, management discussion, or detailed investor presentation content. It is not a report publication announcement since it contains substantive content about the approval and its implications. The document fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about drug approval and related compliance information that does not fit other specific categories like financial reports, management changes, or capital updates.
2024-08-14 Chinese
关于控股股东股份解除质押的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement regarding the release of pledged shares by the controlling shareholder of the company. It details the number of shares released from pledge, the proportion of shares involved, and confirms no further pledge plans at this time. There is no financial report, earnings data, or management discussion. The content fits the category of a Transaction in Own Shares, specifically about share pledge release, which is a capital-related change. Therefore, the appropriate classification is POS (Transaction in Own Shares). The document length is short and it is a direct announcement, not a report publication or certification.
2024-08-06 Chinese
关于不向下修正“灵康转债”转股价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the decision not to downward adjust the conversion price of its convertible bonds ('Lingkang Convertible Bonds'). It details the bond issuance, regulatory approvals, trading information, and the board's resolution on the conversion price adjustment rights. The document is a formal notice about a capital/financing matter related to convertible bonds and their conversion price adjustments. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is clearly an update on a financing condition and board decision related to capital instruments. Therefore, the document fits best under the category 'Capital/Financing Update' (CAP). The document length is short (1865 characters), but it is not merely an announcement of a report publication; it is the substantive announcement itself.
2024-08-06 Chinese
关于“灵康转债”预计满足转股价格修正条件的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Lingkang Pharmaceutical Group Co., Ltd. regarding the expected triggering of the convertible bond's conversion price adjustment conditions. It details the bond's basic information, the adjustment clauses, previous adjustments, and the potential upcoming adjustment due to the stock price falling below a threshold. The document is regulatory in nature, providing a compliance disclosure about convertible bond price adjustments as per stock exchange and securities regulations. It does not contain financial statements, earnings data, or detailed management analysis. It is not a full report but an announcement of a regulatory event related to capital structure and convertible bond terms. Therefore, it fits best under Capital/Financing Update (CAP). The document length is under 5,000 characters, but it is not merely announcing the publication of a report; it is itself the disclosure. Hence, CAP is appropriate with high confidence.
2024-07-30 Chinese
关于控股股东拟非公开发行可交换公司债券对持有的部分本公司股票办理担保及信托登记完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of guarantee and trust registration related to a non-public issuance of exchangeable corporate bonds by the controlling shareholder. It details the shareholding used as collateral and the registration process but does not contain financial statements or detailed financial data. The document is short (847 characters) and serves as an update on financing activities related to capital structure changes. Therefore, it fits best under Capital/Financing Update (CAP).
2024-07-19 Chinese
关于控股股东股票质押式回购交易延期购回的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the delay in the repurchase of pledged shares by the controlling shareholder. It details the number of shares pledged, the extension of the pledge period, and the impact on the company. There is no financial statement, audit information, or detailed report content. The document is a regulatory announcement about a capital/financing event related to stock pledge and repurchase. It is not a full financial report or earnings release, but an update on financing activities involving share pledges. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is short and focused on this specific financing update, not a report publication or certification.
2024-07-19 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.